Related Experiment Video
Updated: Jun 18, 2026

09:54
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Successful treatment with rituximab of one patient with CANOMAD neuropathy
Journal of Neurology
|December 5, 2009
Abstract:
We report a successful treatment with rituximab in a patient with CANOMAD neuropathy resistant to previous therapy. The titers of anti-disialosyl antibodies were decreased 3 months after the beginning of the treatment and the sensory ataxia clearly improved after 9 months of therapy.